DOP2014000103A - COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST - Google Patents

COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST

Info

Publication number
DOP2014000103A
DOP2014000103A DO2014000103A DO2014000103A DOP2014000103A DO P2014000103 A DOP2014000103 A DO P2014000103A DO 2014000103 A DO2014000103 A DO 2014000103A DO 2014000103 A DO2014000103 A DO 2014000103A DO P2014000103 A DOP2014000103 A DO P2014000103A
Authority
DO
Dominican Republic
Prior art keywords
composition
antagonist
proton pump
pump inhibitor
famotidine
Prior art date
Application number
DO2014000103A
Other languages
Spanish (es)
Inventor
María Angélica Arzola Paniagua
Héctor Senosiain Arroyo
Luis Manuel Acosta Gonzáles
Original Assignee
Senosiain S A De C V Lab
Alparis Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab, Alparis Sa De Cv filed Critical Senosiain S A De C V Lab
Publication of DOP2014000103A publication Critical patent/DOP2014000103A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral que comprende la combinación de un inhibidor de la bomba de protones (IBP) y un antagonista H2 (AH2) y sus sales farmacéuticamente aceptables, adicionalmente vehículos o excipientes farmacéuticamente aceptables; así como a un proceso para la fabricación de la composición y al uso de la combinación rabeprazol-famotidina o dexrabeprazol-famotidina con actividad terapéutica sinérgica indicada para el tratamiento de enfermedades de reflujo gastroesofágico (ERGE), escape ácido nocturno (NAB), úlcera péptica y/o erradicación de H. pylori.The present invention relates to an oral pharmaceutical composition comprising the combination of a proton pump inhibitor (IBP) and an H2 antagonist (AH2) and its pharmaceutically acceptable salts, additionally pharmaceutically acceptable carriers or excipients; as well as a process for the manufacture of the composition and the use of the combination rabeprazole-famotidine or dexrabeprazole-famotidine with synergistic therapeutic activity indicated for the treatment of gastroesophageal reflux diseases (GERD), night acid leakage (NAB), peptic ulcer and / or eradication of H. pylori.

DO2014000103A 2013-06-18 2014-05-12 COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST DOP2014000103A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013006980A MX354999B (en) 2013-06-18 2013-06-18 Composition with a proton-pump inhibitor and an h2 antagonist.

Publications (1)

Publication Number Publication Date
DOP2014000103A true DOP2014000103A (en) 2014-12-31

Family

ID=51610703

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000103A DOP2014000103A (en) 2013-06-18 2014-05-12 COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST

Country Status (8)

Country Link
BR (1) BR102014014857A2 (en)
CL (1) CL2014001255A1 (en)
CO (1) CO7020186A1 (en)
CR (1) CR20140220A (en)
DO (1) DOP2014000103A (en)
GT (1) GT201400093A (en)
MX (1) MX354999B (en)
PE (1) PE20150164A1 (en)

Also Published As

Publication number Publication date
CL2014001255A1 (en) 2014-10-10
BR102014014857A2 (en) 2015-06-02
CO7020186A1 (en) 2014-08-11
CR20140220A (en) 2014-08-21
PE20150164A1 (en) 2015-02-25
MX2013006980A (en) 2014-12-19
MX354999B (en) 2018-03-28
GT201400093A (en) 2015-11-16

Similar Documents

Publication Publication Date Title
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
NI201600058A (en) RING-FUSED BICYCLIC PYRIDYL-DERIVED COMPOUNDS AS FGFR4 INHIBITORS
DOP2016000085A (en) AMINO-HETEROARIL-BENZAMIDAS AS CINASA INHIBITORS
EA201690223A1 (en) FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION
UY32455A (en) AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT, AND ITS USES IN THERAPY
ECSP11011526A (en) ARIL-PYRIDINS AS INHIBITORS OF SINTASA DE ALDOSTERONA
CL2012001911A1 (en) Compounds derived from fumarate; pharmaceutical composition comprising them; and its use in the treatment of an inflammatory or neurodegenerative disease.
CO2020006523A2 (en) Sting modulating compounds and methods of manufacture and use
PE20141906A1 (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION REFRACTORY TO TREATMENT OR RESISTANT TO TREATMENT
CL2013000304A1 (en) Compounds derived from prostaglandin e2 inhibitor 2-arylamino-benzimidazoles (mpges-1); pharmaceutical composition that includes them; intermediary compounds; use in the treatment of inflammatory diseases and / or associated conditions, in particular pain.
SV2009003299A (en) USED DIHYDROPIRIDINE DERIVATIVES AS INHIBITORS OF PROTEIN QUINASE
BR112012023021A2 (en) indazole compounds and their uses
CL2015002608A1 (en) Amino-pyrazole compound and related medicinal uses.
GT201400012A (en) INHIBITOR COMPOUND OF THE SIGNALING OF THE NOTCH TRAJECTORY
NI201400111A (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
CR11684A (en) REPLACED DIHYDROPIRAZOLONES OF HIF-PROPIL-4- AS HYDROXYLASE INHIBITORS
CO7350640A2 (en) Dimeric compounds
UY32052A (en) 5-REPLACED AMINOPIRAZOLS AND USE OF THE SAME
DOP2013000131A (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND A MEK INHIBITOR
DOP2019000100A (en) DERIVATIVES OF NAFTIRIDINONE AND ITS USE IN THE TREATMENT OF ARRITMIA
AR087787A1 (en) BENZOTIAZOLONA COMPOSITE
CL2011001829A1 (en) 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.
CU20130004A7 (en) THERAPEUTIC AGENTS 976